The Lund-based company and AFT already work together on manufacturing. The partnership builds on that work by combining CLS’s proprietary non-cooled laser technology with AFT’s expertise in fiber-optic technology and manufacturing. Together, the companies aim to identify and develop specialized laser products for therapeutic use across a wide range of markets. CLS believes the combined commercial potential of these new markets may exceed that of its current ones.

“The agreement is an important step toward unlocking the broader commercial potential of our technology. While our current business is mainly focused on neurosurgery, we see significant opportunities in other therapeutic areas that CLS has so far largely left unexplored. Together with AFT, we aim to pursue them through a partnership that also makes efficient use of our resources,” says Dan Johansson Mogren, CEO of CLS.

“Our long-standing collaboration with CLS provides a strong foundation for further innovation. By combining our complementary technologies and expertise, we see opportunities to develop differentiated products that meet new therapeutic needs,” says Naim Ashraf, CSO of AFT.

The agreement is non-exclusive and sets a framework for evaluating opportunities. Individual development and commercialization projects will be agreed separately. The deal carries no immediate financial commitments or guaranteed volumes, and it does not affect the companies’ existing manufacturing agreement.